APOL1风险变异与新发血液透析患者的亚临床心血管疾病
本研究在267例开始血液透析的非裔美国人中,评估APOL1高风险状态(2个风险等位基因)与基线亚临床心血管疾病及死亡率的关联。结果显示,高风险状态与左心室肥厚和冠状动脉钙化的 odds 分别降低50%和53%独立相关,左心室质量降低10.7%,但与全因或心血管死亡率无关。
要点
- APOL1高风险状态与左心室肥厚 odds 降低50%相关。
- APOL1高风险状态与冠状动脉钙化 odds 降低53%相关。
- APOL1风险状态与2.5年随访的全因或心血管死亡率无关。
核心结论
- 在非裔新发血液透析患者中,APOL1高风险状态与更好的亚临床心血管疾病指标相关,但与死亡率无关。
研究设计与样本
- 基于Predictors of Arrhythmic and Cardiovascular Risk in ESRD队列研究,纳入267例成功进行APOL1基因分型的非裔美国人,平均年龄53岁,41%为女性。
主要发现
- APOL1高风险状态与左心室肥厚 odds 降低50%独立相关。
- APOL1高风险状态与冠状动脉钙化 odds 降低53%独立相关。
- APOL1高风险状态与左心室质量降低10.7%独立相关。
- 进一步调整合并症后上述关联稳健,但调整收缩压后不再显著。
- APOL1风险状态与全因或心血管死亡率无关(平均随访2.5年)。
关键数值与推荐
- APOL1高风险定义为携带2个风险等位基因,低风险定义为0或1个风险等位基因。
- 亚临床心血管疾病指标包括左心室肥厚、左心室质量、射血分数、冠状动脉钙化及脉搏波传导速度。
临床怎么用
- 在非裔新发血液透析患者中,APOL1高风险状态可能提示较低的亚临床心血管疾病负担,但需结合血压等因素综合评估。
局限性
- 关联在调整收缩压后不再显著,提示血压可能介导或混杂部分关联。
- 随访时间较短(平均2.5年),死亡率分析可能受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: To better understand the impact of APOL1 risk variants in end-stage renal disease (ESRD) we evaluated associations of APOL1 risk variants with subclinical cardiovascular disease (CVD) and mortality among African Americans initiating hemodialysis and enrolled in the Predictors of Arrhythmic and Cardiovascular Risk in ESRD cohort study. METHODS: We modeled associations of APOL1 risk status (high = 2; low = 0/1 risk alleles) with baseline subclinical CVD (left ventricular [LV] hypertrophy; LV mass; ejection fraction; coronary artery calcification [CAC]; pulse wave velocity [PWV]) using logistic and linear regression and all-cause or cardiovascular mortality using Cox models, adjusting for age, sex, and ancestry. In sensitivity analyses, we further adjusted for systolic blood pressure and Charlson Comorbidity Index. RESULTS: Of 267 African American participants successfully genotyped for APOL1, 27% were high-risk carriers, 41% were women, and mean age was 53 years. At baseline, APOL1 high- versus low-risk status was independently associated with 50% and 53% lower odds of LV hypertrophy and CAC, respectively, and 10.7% lower LV mass. These associations were robust to further adjustment for comorbidities but not systolic blood pressure. APOL1 risk status was not associated with all-cause or cardiovascular mortality (mean follow-up 2.5 years). CONCLUSION: Among African American patients with incident hemodialysis, APOL1 high-risk status was associated with better subclinical measures of CVD but not mortality.
引用
- Chen TK, Fitzpatrick J, Winkler CA, et al. APOL1 Risk Variants and Subclinical Cardiovascular Disease in Incident Hemodialysis Patients. Kidney Int Rep. 2020. PMID: 33615058. doi:10.1016/j.ekir.2020.11.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。